StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$3.02+0.14 (+4.86%)

Close on Nov 18, 2026Market cap $243.33MP/E 13.1Yield –

Protalix BioTherapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Protalix BioTherapeutics's price to book ratio was 3.6× on Nov 11, 2026, against 2.9× a year earlier. Over the last 5 years it ranged from 2.5× to 178.3×, with a median of 3.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.6×+0.7
2025Dec 31, 20252.9×−1.6
2024Dec 31, 20244.6×+1.3
2023Dec 29, 20233.2×−159.1
2022Jan 31, 2022162.3×+2.0
2021Dec 31, 2021160.3×+136.6
2016Jul 29, 201623.7×−72.7
2013Jan 31, 201396.4×−1.5
2012Dec 31, 201297.9×–

More Protalix BioTherapeutics figures

See a number that looks wrong?